Dr. Debbie Lin is Executive Director at Boehringer Ingelheim Venture Fund in the US and started and leads the Fund’s North American investment efforts in Digital Healthcare. She led the investments for and has Board Directorship roles at Wellth Inc. (New York, NY) and Bodyport Inc. (San Francisco, CA). She joined Boehringer Ingelheim Pharmaceuticals in 2008. Within Boehringer Ingelheim Pharma, she worked across various regions and divisions in both the USA and at the Corporate Headquarters in Germany. She has worked in Medical Affairs in the area of central nervous systems /women’s health and later in Health Economics and Outcomes regionally, supporting sales and marketing with all commercial product sales and launches to payers and health systems in the Western region of the US including Kaiser Permanente (CA, WA, OR, CO, Hawaii), Health Net, Blue Shield of California, Providence Health, Department of Defence, State Medicaid, among others. She also supported non-brand efforts, working with teams to develop disease management programs and trained all levels of healthcare providers to implement them in their health systems. During this time she also led BI USA’s social entrepreneurship program Making More Health and growing the impact of the program globally.
In 2013, she transitioned to Corporate Headquarters in Germany in Corporate Strategy and Development as Global Director of Corporate Development. There she was responsible for BI’s corporate global development strategy, working with various teams in Germany and across Europe and Asia, crafting BI’s future global corporate development strategy and leading BI’s global venture into stroke rehabilitation. She developed the strategy for, secured funding for and led multi-country teams to negotiate and set up the company’s first Consanas stroke rehabilitation centers in Shanghai, China and in Lisbon, Portugal, bringing a model of stroke rehabilitation from Germany to China and Portugal. Prior to Boehringer Ingelheim, she worked as a Public Policy Consultant for Pacific Health Policy Group supporting Medicaid Policy implementation in various states such as Vermont and West Virginia during the Clinton Administration. She also consulted for Roche Bioscience helping to evaluate new genomics technologies. Her doctorate is in Pharmacogenomics and Bioinformatics from UCSF, she also has a Masters in Engineering from Stanford University and a Masters in Public Policy from UCLA.
Debbie is attending / has attended:
The 2019 New England Venture Summit
Venture Summit | West 2020
Venture Summit Virtual Connect | Global 21